Surface Oncology (NASDAQ:SURF) Announces Quarterly Earnings Results

Surface Oncology (NASDAQ:SURF) announced its quarterly earnings data on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.01), MarketWatch Earnings reports. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 32.89%.

Shares of NASDAQ:SURF opened at $9.28 on Friday. The company has a quick ratio of 11.12, a current ratio of 11.12 and a debt-to-equity ratio of 0.16. Surface Oncology has a 52-week low of $1.38 and a 52-week high of $10.25. The company has a 50 day moving average of $8.15 and a two-hundred day moving average of $5.94. The company has a market capitalization of $370.33 million, a price-to-earnings ratio of -10.55 and a beta of 2.40.

In other Surface Oncology news, insider Robert W. Ross sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $10.05, for a total value of $40,200.00. Following the completion of the sale, the insider now owns 101,000 shares of the company’s stock, valued at $1,015,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 35.00% of the stock is owned by company insiders.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Surface Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Wedbush assumed coverage on shares of Surface Oncology in a research report on Thursday, August 27th. They set an “outperform” rating and a $12.00 target price for the company. BidaskClub raised shares of Surface Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, September 10th. Finally, HC Wainwright assumed coverage on shares of Surface Oncology in a research report on Friday, September 4th. They set a “buy” rating and a $11.00 target price for the company. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $9.63.

Surface Oncology Company Profile

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R.

Read More: Quiet Period Expirations

Earnings History for Surface Oncology (NASDAQ:SURF)

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit